Inhibikase Therapeutics (Nasdaq:IKT) - Hisse Senedi Fiyatı, Haberler ve Analizler

IKT Stoklara Genel Bakış

Klinik aşamada bir ilaç şirketi olan Inhibikase Therapeutics, Inc. Parkinson hastalığı ve ilgili bozukluklar için terapötikler geliştirmektedir. Daha fazla detay

IKT temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Geliri 1 milyon ABD dolarından az ( $1 )

Negatif hissedar öz sermayesi

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

+ 1 daha fazla risk

Inhibikase Therapeutics, Inc. Rakipler

Cibus

NasdaqCM:CBUS

US$109.5m

XBiotech

NasdaqGS:XBIT

US$208.2m

Kyverna Therapeutics

NasdaqGS:KYTX

US$189.5m

Leap Therapeutics

NasdaqCM:LPTX

US$97.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Inhibikase Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$2.34
52 Haftanın En Yüksek Seviyesi	US$3.82
52 Haftanın En Düşük Seviyesi	US$0.85
Beta	1.12
11 Aylık Değişim	-3.31%
3 Aylık Değişim	67.14%
1 Yıllık Değişim	162.92%
33 Yıllık Değişim	-81.69%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-96.06%

Son Haberler & Güncellemeler

Recent updates

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Apr 06

Hissedar Getirileri

	IKT	US Biotechs	US Pazar
7D	18.8%	2.5%	2.2%
1Y	162.9%	16.1%	31.6%

Getiri vs. Endüstri: IKT geçen yıl % 16.1 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: IKT geçen yıl % 31.6 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is IKT's price volatile compared to industry and market?
IKT volatility
IKT Average Weekly Movement	14.6%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: IKT hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: IKT 'nin haftalık oynaklığı ( 15% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2008	9	Milton Werner	www.inhibikase.com

Klinik aşamada bir ilaç şirketi olan Inhibikase Therapeutics, Inc. Parkinson hastalığı ve ilgili bozukluklar için terapötikler geliştirmektedir. Şirketin öncü ürün adayı, Parkinson hastalığı ve gastrointestinal sistem tedavisi için Faz 2a klinik çalışmalarında olan, reseptör olmayan bir Abelson tirozin kinaz inhibitörü olan IkT-148009'dur. Şirket ayrıca stabil faz kronik miyelojenöz lösemiyi tedavi etmek için antikanser ajan imatinib mesilat ön ilacı olan IkT-001Pro'yu geliştirmektedir.

Inhibikase Therapeutics, Inc. Temel Bilgiler Özeti

Inhibikase Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IKT temel i̇stati̇sti̇kler
Piyasa değeri	US$155.21m
Kazançlar(TTM)	-US$19.57m
Gelir(TTM)	US$1.00

Over9,999x

P/S Oranı

-8.0x

F/K Oranı

IKT aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IKT gelir tablosu (TTM)
Gelir	US$1.00
Gelir Maliyeti	US$13.02m
Brüt Kâr	-US$13.02m
Diğer Giderler	US$6.55m
Kazançlar	-US$19.57m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.29
Brüt Marj	-1,301,996,100.00%
Net Kâr Marjı	-1,956,524,900.00%
Borç/Özkaynak Oranı	-13.5%

IKT uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

IKT Stoklara Genel Bakış

Risk Analizi

Inhibikase Therapeutics, Inc. Rakipler

NasdaqCM:CBUS

US$109.5m

NasdaqGS:XBIT

US$208.2m

NasdaqGS:KYTX

US$189.5m

NasdaqCM:LPTX

US$97.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New major risk - Negative shareholders equity

Third quarter 2024 earnings released: US$0.65 loss per share (vs US$0.86 loss in 3Q 2023)

New major risk - Shareholder dilution

Insufficient new directors

Inhibikase Therapeutics, Inc. announced that it has received $109.982165 million in funding from a group of investors

Inhibikase Therapeutics, Inc. announced that it expects to receive $109.982165 million in funding from a group of investors

Recent updates

New major risk - Negative shareholders equity

Third quarter 2024 earnings released: US$0.65 loss per share (vs US$0.86 loss in 3Q 2023)

New major risk - Shareholder dilution

Insufficient new directors

Inhibikase Therapeutics, Inc. announced that it has received $109.982165 million in funding from a group of investors

Inhibikase Therapeutics, Inc. announced that it expects to receive $109.982165 million in funding from a group of investors

Inhibikase Therapeutics, Inc. Announces Board Changes

First half 2024 earnings released: US$1.39 loss per share (vs US$2.08 loss in 1H 2023)

Inhibikase Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million.

First quarter 2024 earnings released: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)

Inhibikase Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

New major risk - Market cap size

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Full year 2023 earnings: EPS misses analyst expectations

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.659255 million.

New major risk - Share price stability

Consensus revenue estimates increase by 44%

Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024

Inhibikase Therapeutics, Inc. Provides Update on Development Programs

Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Third quarter 2023 earnings released: US$0.86 loss per share (vs US$1.07 loss in 3Q 2022)

Inhibikase Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib

Consensus revenue estimates increase by 178%, EPS downgraded

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro

New major risk - Financial position

Second quarter 2023 earnings released: US$1.11 loss per share (vs US$1.10 loss in 2Q 2022)

Inhibikase Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Inhibikase Therapeutics Announces 1-For-6 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Inhibikase Therapeutics, Inc. Initiates Medical and Patient Awareness Campaign for Its Phase 2 '201' Trial Evaluating It-148009 in Parkinson's Disease

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022)

Inhibikase Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023

Inhibikase Therapeutics, Inc. announced that it expects to receive $4.199512 million in funding

Inhibikase Therapeutics Announces Publication Demonstrating Potential for C-Abl as A Key Therapeutic Target in Parkinson's Disease and Related Disorders

Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Inhibikase Therapeutics, Inc. Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics, Inc. Provides Update to FDA Clinical Hold of IkT-148009 Programs

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.18 loss in 3Q 2021)

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Inhibikase Therapeutics, Inc Announces FDA Clinical Hold on IkT-148009 Programs

High number of new and inexperienced directors

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Executive Changes

Inhibikase Therapeutics, Inc Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia

Inhibikase Therapeutics, Inc. Doses First Patient in Its Phase 2a '201' Clinical Trial of IKT-148009 to Treat Parkinson's Disease

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M

Inhibikase Therapeutics, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?